CFO transition
HeartSciences Inc. CFO transition: Erik Ellingson to succeed Danielle Watson
HeartSciences Inc. reported in a Form 8-K filed June 26, 2026 that Erik Ellingson will succeed Danielle Watson as Chief Financial Officer.
In the filing's words
for Mr. Ellingson to be appointed as the new Chief Financial Officer of HeartSciences to replace Ms. Watson, HeartSciences’ current Chief Financial Officer.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | HeartSciences Inc. (HSCS) |
|---|---|
| Event | Transition |
| Incoming | Erik Ellingson |
| Outgoing | Danielle Watson |
| Title in the filing | Chief Financial Officer |
| Effective | not stated in the source |
| 8-K filed | June 26, 2026 |
| Internal promotion | Not established by the source |
| SEC CIK | 0001468492 |
HeartSciences Inc. reported this change in a Form 8-K, Item 5.02, filed June 26, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Documented unknowns
- effective: The filing gives "the Effective Time", which is not a calendar date.
Something wrong about Erik Ellingson? Send a correction with the primary source.